banner-01_about-us-copy

Board of Directors

The Rubicon Core Group has a synergistic composition of working directors, each with a specialization that has withstood the toughest tests of result-oriented international business environment.

Ms. Pratibha Pilgaonkar B.Sc. (Chem), B.Sc. (Tech) UICT, India
Chief Executive Officer, Board of Directors, Scientific Advisory Board

Mrs. Pilgaonkar is unique in that she combines Innovative and technical leadership with a vision to establish various R&D organizations of Global significance. She started her career in Burroughs Welcome (GlaxoSmithKline) in 1977 as a formulation development scientist. As head of product development at Ciba Geigy (Novartis), she pioneered formulation development outsourcing efforts from India in 1991 thus-laying the foundation of current Sandoz Research Center in Mumbai. As Vice President, R & D she played a major role in development of Sun Pharma’s Advanced Research Center – (SPARC), Mumbai and was instrumental in successful technology transfer of several products to the Caraco plant in Michigan.

This stellar professional career path has enriched the lives of many budding technocrats and entrepreneurs as Mrs. Pilgaonkar has mentored them for “out of the box” thinking. Mrs. Pilgaonkar has numerous patents and publications to her credit and has developed platform technologies in the area of controlled release, gastric retention, orally disintegrating tablets, tablet for suspension, taste masking and pediatric formulations.

Her alma mater is the prestigious UICT, (University Institute of Chemical Technology) where she graduated in Chemical Technology in 1976. In her spare time, Mrs. Pilgaonkar enjoys gardening, listening to Indian Classical and Folk Music and taking short trips to the countryside.

Ms. Maharukh Rustomjee M.Pharm (Pharmaceutics) UICT, India
Chief Operating Officer and Founder, Board of Directors, Scientific Advisory Board

Ms. Rustomjee has a wide range of experience spanning 25 years in product development. She was Manager – Product Development for Novartis, India and contributed significantly in taking forward the R&D initiative at Sandoz Research Center. She headed various research as well as business leads in her prior stints at Hindustan Ciba Geigy (Novartis) and Burroughs Wellcome (GlaxoSmithKline). At Ciba Geigy, Ms. Rustomjee actively participated in Business Opportunity Assessment project implementation and improving efficiencies in product development in collaboration with McKinsey and Co. Her prowess at design and execution is evident in the successful completion of highly complex projects such as developing and manufacturing special packs for anti-TB products and leprosy programs for WHO program which has been implemented in developing countries. Ms. Rustomjee is widely known not only for her thought leadership but also her tremendous resource mobilization capability. She also is an inventor of numerous patents in the area of drug delivery systems. Her collaboration with Ms. Pilgaonkar dates back to Novartis and GlaxoSmithKline days.

Mrs. Rustomjee’s alma mater is also the prestigious UICT, (University Institute of Chemical Technology) where she graduated in Pharmaceutical Technology in 1982. In her spare time, Mrs. Rustomjee enjoys music, catching up on movies and taking short vacations with her family.

Mr. Sudhir Pilgaonkar B.Sc. (Chem), B.Sc. (Tech) UICT, India
Chief Commercial Officer and Founder, Board of Directors

Mr. Pilgaonkar has over 30 years of experience in technical operations and manufacturing valued added specialty pharmaceutical products. During his stint at Hoechst (Sanofi Aventis), he headed the inventory control function for Pharma and Agro Divisions in India and achieved high process excellence in streamlining inventory management systems for both the SBUs. He has technical operations experience spanning from fine chemicals to finished formulations. These diverse techno-commercial skill-sets acquired at Hoechst (Sanofi Aventis) spurred on his entrepreneurial venture: Galentic Pharma – a sterile products and specialty manufacturing unit which he successfully set up and operated as a Greenfield project. His responsibilities at Rubicon include complete resource management and commercial functions.

Mr. Pilgaonkar’s alma mater is the prestigious UICT as well, (Mumbai University Institute of Chemical Technology) where he graduated in Chemical Technology in 1976. Mr. Pilgaonkar enjoys food, quality time with his family and friends and looks forward to taking short breaks at his country home.

Dr. L.S. Rao B.Sc. (Chem), M.Sc. (Chem), PhD (Chem), India
Chief Scientific Officer, Scientific Advisory Board

Dr. Rao has over 35 years of pharmaceutical research experience coupled with regulatory expertise. He has numerous patents and publications in the area of drug delivery systems. Dr Rao had positions of responsibility at Wellcome Foundation (GlaxoSmithKline) at Kent (U.K.). He was also head of Product Development at Indian operations of Burroughs Wellcome (GlaxoSmithKline). During his stint at GlaxoSmithKline he was responsible for various NDA applications including Zovirax and novel liposomal formulations. His most recent assignments included heading scientific affairs at Chauvin Pharmaceuticals Ltd (U.K.) and Smith and Nephew Pharmaceuticals Ltd (U.K.) He is widely regarded as an expert in developing complex dosage forms such as AMETOP®, NODS® (Novel Opthalmic Delivery System), MINIMS® format, development of an aqueous suspension formulation of acyclovir for the treatment of herpes simplex keratitis amongst many others. Dr. Rao is a Fellow of the Royal Society of Chemistry and Member of the British Institute of Regulatory Affairs.

Mr. Nitin Deshmukh M.Pharm (UICT), MBA
Kotak Mahindra Pvt Equity, Board of Directors

Mr. Deshmukh is the founding member of the Private Equity practice at Kotak and has played the pivotal role in raising US$ 650 million funds, currently under management. He has led and managed investments in over 60 companies, a significant number of which have grown at a scorching pace attaining leadership position in their respective sectors. Prior to taking up the current assignment at Kotak in June 2004, Mr. Deshmukh was Director with SEAF, a US headquartered Venture Capital fund. He was the founding member of the India Team of Dresdner Kleinwort Capital when it started operations in India in June 2001. Prior to joining Dresdner, Mr. Deshmukh had a long stint of over 12 years with ICICI Venture, the PE and VC arm of the ICICI Group from its inception in 1989 to being its Chief of Private Equity Investments. During his association with ICICI Venture he led its investment strategy in life sciences (pharmaceuticals & biotechnology), media/entertainment and retailing industries achieving high returns for its investors by investing in these sectors much ahead of competition. KPEG has invested in Rubicon in 2007 and advises Rubicon on strategic and business initiatives.